Intestinal metabolism and transport of drugs in children: The effects of age and disease

Journal of Pediatric Gastroenterology and Nutrition

Volumn 47, Issue 1, 2008, Pages 3-10

  Johnson, Trevor N ^a   Thomson, Mike ^a  

^a SHEFFIELD CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

Cytochrome P450 enzymes; Intestinal drug metabolism; P glycoprotein

Indexed keywords

ANTIBIOTIC AGENT; BUDESONIDE; CARRIER PROTEIN; CYCLOSPORIN A; CYTOCHROME P450; DICLOFENAC; ENZYME; ERYTHROMYCIN; GLYCOPROTEIN P; KETOCONAZOLE; LIDOCAINE; MIDAZOLAM; NIFEDIPINE; OMEPRAZOLE; SAQUINAVIR; SILDENAFIL; TACROLIMUS; TERBUTALINE; XENOBIOTIC AGENT; CYCLOSPORIN;

CHILD; COLITIS; CROHN DISEASE; DISEASE ASSOCIATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG EFFECT; DRUG METABOLISM; DRUG TRANSPORT; FOOD DRUG INTERACTION; GASTROINTESTINAL DISEASE; GASTROINTESTINAL TRACT; GRAPEFRUIT JUICE; HUMAN; NONHUMAN; NUTRITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SMALL INTESTINE; AGING; BIOAVAILABILITY; DOSE RESPONSE; ENZYMOLOGY; GASTROINTESTINAL TRANSIT; INTESTINE ABSORPTION; LIVER; METABOLISM; PHYSIOLOGY; TISSUE DISTRIBUTION;

AGING; BIOLOGICAL AVAILABILITY; CHILD; CYCLOSPORINE; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; GASTROINTESTINAL TRANSIT; HUMANS; INTESTINAL ABSORPTION; INTESTINE, SMALL; LIVER; MIDAZOLAM; TISSUE DISTRIBUTION;

EID: 55549143695     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPG.0b013e31816a8cca     Document Type: Review

References (54)

1. Kearns GL, Abdel-Rahman SM, Alander SW, et al. Developmental pharmacology: drug disposition, action and therapy in infants and children. N Engl J Med 2003;349:1157-67.
2. Nelson DR, Koymans L, Kamataki T, et al. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996;6:1-42.
3. Wrighton SA, Brian WR, Sari MA, et al. Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol Pharmacol 1990;38:207-13.
4. Johnson TN, Rostami-Hodjegan A, Tucker GT. Prediction of the clearance of eleven drugs and associated variability in neonates, infants, and children. Clin Pharmacokinet 2006;45:931-56.
5. Lacroix D, Sonnier M,Moncion A, et al. Expression ofCYP3A in the human liver: evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth. Eur J Biochem 1997;247:625-34.
6. Hines RN, McCarver DG. The ontogeny of human drug-metabolizing enzymes: phase I oxidative enzymes. J Pharmacol Exp Ther 2002;300:355-60.
7. McCarver DG, Hines RN. The ontogeny of human drug-metabolizing enzymes: phase II conjugation enzymes and regulatory mechanisms. J Pharmacol Exp Ther 2002;300:361-6.
8. BurtinP, Jacqz-AigrainE,GirardP, et al.Populationpharmacokinetics of midazolam in neonates. Clin Pharmacol Ther 1994;56:615-25.
9. Hughes J, Gill AM, Mulhearn H, et al. Steady-state plasma concentrations of midazolam in critically ill infants and children. Ann Pharmacother 1996;30:27-30.
10. Watkins PB, Wrighton SA, Schuetz EG, et al. Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. J Clin Invest 1987;80:1029-36.
11. Murray GI, Barnes TS, Sewell HF, et al. The immunocytochemical localisation and distribution of cytochrome P-450 in normal human hepatic and extrahepatic tissues with a monoclonal antibody to human cytochrome P-450. Br J Clin Pharmacol 1988;25:465-75.
12. Paine MF, Khalighi M, Fisher JM, et al. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther 1997;283:1552-62.
13. Paine MF, Hart HL, Ludington SS, et al. The human intestinal cytochrome P450 "pie". Drug Metab Dispos 2006;34:880-6.
14. Lown KS, Kolars JC, Thummel KE, et al. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel: lack of prediction by the erythromycin breath test. Drug Metab Dispos 1994;22:947-55.
15. Kolars JC, Awni WM, Merion RM, et al. First-pass metabolism of cyclosporin by the gut. Lancet 1991;338:1488-90.
16. Paine MF, Shen DD, Kunze KL, et al. First-pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther 1996;60: 14-24.
17. Zhang Y, Benet LZ. The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet 2001;40:159-68.
18. Wacher VJ, Wu CY, Benet LZ. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 1995;13:129-34.
19. Watkins PB. The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv Drug Deliv Rev 1997;27:161-70.
20. Webber IR, Peters WH, Back DJ. Cyclosporin metabolism by human gastrointestinal mucosal microsomes. Br J Clin Pharmacol 1992;33:661-4.
21. Gomez DY, Wacher VJ, Tomlanovich SJ, et al. The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin Pharmacol Ther 1995;58:15-9.
22. Ducharme MP, Warbasse LH, Edwards DJ. Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. Clin Pharmacol Ther 1995;57:485-91.
23. Lown KS, Mayo RR, Leichtman AB, et al. Role of intestinal Pglycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 1997;62:248-60.
24. Hashida T, Masuda S, Uemoto S, et al. Pharmacokinetic and prognostic significance of intestinal MDR1 expression in recipients of living-donor liver transplantation. Clin Pharmacol Ther 2001;69: 308-316.
25. Tolle-Sander S, Rautio J, Wring S, et al. Midazolam exhibits characteristics of a highly permeable P-glycoprotein substrate. Pharm Res 2003;20:757-64.
26. Thummel KE, O'Shea D, Paine MF, et al. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3Amediated metabolism. Clin Pharmacol Ther 1996;59:491-502.
27. Tsunoda SM, Velez RL, von Moltke LL, et al. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole. Clin Pharmacol Ther 1999;66:461-71.
28. Kupferschmidt HH, Ha HR, Ziegler WH, et al. Interaction between grapefruit juice and midazolam in humans. Clin Pharmacol Ther 1995;58:20-8.
29. Fontana RJ, Lown KS, Paine MF, et al. Effects of a chargrilled meat diet on expression of CYP3A, CYP1A, and P-glycoprotein levels in healthy volunteers. Gastroenterology 1999;117:89-98.
30. Johnson TN, Tanner MS, Tucker GT. A comparison of the ontogeny of enterocytic and hepatic cytochromes P450 3A in the rat. Biochem Pharmacol 2000;60:1601-10.
31. Johnson TN, Tanner MS, Taylor CJ, et al. Enterocytic CYP3A4 in a pediatric population: developmental changes and the effect of celiac disease and cystic fibrosis. Br J Clin Pharmacol 2001;51:451-60.
32. Miki Y, Suzuki T, Tazawa C, et al. Steroid and xenobiotic receptor (SXR), cytochrome P450 3A4 and multidrug resistance gene 1 in human adult and fetal tissues. Mol Cell Endocrinol 2005;231:75-85.
33. Fakhoury M, Litalien C, Medard Y, et al. Localization and mRNA expression of CYP3A and P-glycoprotein in human duodenum as a function of age. Drug Metab Dispos 2005;33:1603-7.
34. Blake MJ, Abdel-Rehman SM, Pearce RE, et al. Effects of diet on the development of drug metabolism by cytochrome P-450 enzymes in healthy infants. Pediatr Res 2006;60:717-23.
35. van Kalken C, Giaccone G, van der Valk P, et al. Multidrug resistance gene (P-glycoprotein) expression in the human fetus. Am J Pathol 1992;141:1063-72.
36. Taketomo CK, Hodding JH, Kraus DM. Pediatric Dosage Handbook International. 13th ed. Hudson, OH: Lexi-Comp; 2006.
37. Wu C-Y, Benet LZ. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 2005;22:11-23.
38. Paine MF, Thummel KE. Role of intestinal cytochromes P450 in drug disposition. In: Lee JS, Obach RS, Fisher MB (eds). Drug Metabolizing Enzymes. New York and Lausanne, Switzerland: Marcel Dekker and Fontis Media; 2003. pp. 421-51.
39. Hoppu K, Koskimies O, Holmberg C, et al. Evidence for pre-hepatic metabolism of oral cyclosporin in children. Br J Clin Pharmacol 1991;32:477-81.
40. Cooney GF, Habucky K, Hoppu K. Cyclosporin pharmacokinetics in pediatric transplant recipients. Clin Pharmacokinet 1997;32:481- 95.
41. Brunner LJ, Pai KS, Munar MY, et al. Effect of grapefruit juice on cyclosporin A pharmacokinetics in pediatric renal transplant patients. Pediatr Transplant 2000;4:313-21.
42. Fanta S, Jonsson S, Backman JT, et al. Developmental pharmacokinetics of ciclosporin: a population pharmacokinetic study in pediatric renal transplant candidates. Br J Clin Pharmacol 2007;64:772-84.
43. Masuda S, Uemoto S, Goto M, et al. Tacrolimus therapy according to mucosal MDR1 levels in small bowel transplant recipients. Clin Pharmacol Ther 2004;75:352-61.
44. de Wildt SN, Kearns GL, Hop WC, et al. Pharmacokinetics and metabolism of oral midazolam in preterm infants. Br J Clin Pharmacol 2002;53:390-2.
45. Edsbacker S,AnderssonT. Pharmacokinetics ofbudesonide (Entocort EC) capsules for Crohn's disease. ClinPharmacokinet 2004;43:803- 21.
46. Lang CC, Brown RM, Kinirons MT, et al. Decreased intestinal CYP3A in celiac disease: reversal after successful gluten-free diet: a potential source of interindividual variability in first-pass drug metabolism. Clin Pharmacol Ther 1996;59:41-6.
47. Hoensch HP, Hartmann F. The intestinal enzymatic biotransformation system: potential role in protection from colon cancer. Hepatogastroenterology 1981;28:221-8.
48. Holmes GK. Celiac disease and malignancy. J Pediatr Gastroenterol Nutr 1997;24:S20-4.
49. Maezono S, Sugimoto K, Sakamoto K, et al. Elevated blood concentrations of calcineurin inhibitors during diarrhael episode in pediatric liver transplant recipients: involvement of the suppression of intestinal cytochrome P450 3A and P-glycoprotein. Pediatr Transplant 2005;9:315-23.
50. Klotz U, Hoensch H, Schutz T, et al. Expression of intestinal drugmetabolizing enzymes in patients with chronic inflammatory bowel disease. Current Ther Res 1998;556:556-63.
51. Schwab M, Schaeffeler E, Marx C, et al. Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. Gastroenterology 2003;124:26-33.
52. Maggio-Price L, Shows D, Waggie K, et al. Helicobacter bilis infection accelerates and H. hepaticus infection delays the development of colitis in multiple drug resistance-deficient (mdr1a-/-) mice. Am J Pathol 2002;160:739-51.
53. Panwala CM, Jones JC, Viney JL. A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdr1a,spontaneouslydevelopcolitis. JImmunol 1998;161:5733-44.
54. Ho GT, Moodie FM, Satsangi J. Multidrug resistance 1 gene (P-glycoprotein 170): an important determinant in gastrointestinal disease? Gut 2003;52:759-66.